Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis

CD47 is a prominent new target in cancer immunotherapy, with antagonistic antibodies currently being evaluated in clinical trials. For effective evaluation of this strategy it is crucial to identify which patients are suited for CD47-targeted therapy. In this respect, expression of the pro-phagocyti...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yuan, Bouwstra, Renee, Wiersma, Valerie R., de Jong, Mathilde, Jan Lourens, Harm, Fehrmann, Rudolf, de Bruyn, Marco, Ammatuna, Emanuele, Huls, Gerwin, van Meerten, Tom, Bremer, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358615/
https://www.ncbi.nlm.nih.gov/pubmed/30710089
http://dx.doi.org/10.1038/s41467-018-08013-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358615/
https://www.ncbi.nlm.nih.gov/pubmed/30710089
http://dx.doi.org/10.1038/s41467-018-08013-z

Ejemplares similares